Erenumab for episodic migraine

被引：5

作者：

Datta, Abhigyan ^{[1
]}

Gupta, Sahil ^{[2
]}

Maryala, Shashi ^{[3
]}

Aggarwal, Vikram ^{[4
]}

Chopra, Pooja ^{[5
]}

Jain, Sameer ^{[6
]}

机构：

[1] Maulana Azad Med Coll, New Delhi 110002, India

[2] Southern Illinois Healthcare, Carbondale, IL 62901 USA

[3] Gandhi Med Coll, Secunderabad 500003, Telangana, India

[4] UT Southwestern Med Ctr, Dallas, TX 75390 USA

[5] Bux Pain Management, 217 3rd St, Danville, KY 40422 USA

[6] Pain Treatment Ctr Amer, Little Rock, AR 72205 USA

来源：

PAIN MANAGEMENT | 2022年 / 12卷 / 05期

关键词：

Aimovig; CGRP antagonists; episodic migraine; erenumab; headache; migraine; GENE-RELATED PEPTIDE; DOUBLE-BLIND; AMG; 334; PATHOPHYSIOLOGY; EFFICACY; HEALTHY; SAFETY; TRIAL;

D O I：

10.2217/pmt-2021-0077

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In this review, the authors provide an overview of erenumab, a monoclonal antibody used for the preventative treatment of episodic migraine by targeting the CGRP pathway. Randomized controlled trials have shown that erenumab is associated with a statistically significant decrease in monthly migraine days in patients with episodic migraine at monthly doses of 70 or 140 mg when given for a period of 9-12 weeks. Post hoc analyses have also shown long-term maintenance of efficacy. Clinical trials have found erenumab at doses of both 70 and 140 mg to have a favorable safety profile. Erenumab faces significant limitations because of its high financial cost. Additional long-term real-world data are needed to understand the role of erenumab in the treatment of migraine.

引用

页码：587 / 594

页数：8

共 52 条

[41] Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study [J].